Skip to main navigation Skip to search Skip to main content

The gene product of CBFB-MYH11

  • David Claxton
  • , Q. S. Xie
  • , S. Patel
  • , A. B. Deisseroth
  • , S. Kornblau

Research output: Contribution to journalArticlepeer-review

Abstract

The inversion(16)(p13;q22) gives rise to chimeric transcripts CBFB-MYH11. To date however, no reports have described the full length coding sequence cloned from patient material or the protein product derived from transcripts. We describe here the cloning and sequencing of the coding region of the fusion gene (type A) from patient cells. The sequence is identical to the included portions of the normal constituent transcripts. We report the study of CBFB and CBFB-MYH11 protein using two anti-CBFB antisera. Twenty-two cases of inv(16) leukemia and a number of other cases of AML were examined. The predicted 70 kDa type A or 95 kDa type D CBFB-MYH11 peptide was detected in 20/22 cases of inv(16) AML. CBFB was expressed as a 21 kDa protein in all samples studied, including hematopoietic cell lines of all major lineages.

Original languageEnglish (US)
Pages (from-to)1479-1485
Number of pages7
JournalLeukemia
Volume10
Issue number9
StatePublished - Sep 1996

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The gene product of CBFB-MYH11'. Together they form a unique fingerprint.

Cite this